Particularly, through a proteomic approach, the interaction between MMP-9 and NGAL (neutrophil gelatinase-associated lipocalin) has been associated with plaque vulnerability, and MMP-9/NGAL has been proposed as a target of statins in patients with CS [102]. The gene discussed is LCN2; the disease is Cowden syndrome 1.